Overview
- Innovent will advance programs from concept through Phase 2 proof-of-concept in China, after which Lilly takes development and commercialization outside Greater China while Innovent retains local rights.
- Lilly receives an exclusive license for territories beyond Greater China, formalizing a clear split of responsibilities and markets.
- Milestone payments are contingent on future development, regulatory and commercial achievements under the agreement.
- This marks the partners’ seventh collaboration, extending a relationship that spans more than a decade.
- Innovent cites 16 marketed products and a broad late- and early-stage pipeline as the base for accelerating global reach through this model.